重性抑郁障碍辅助抗精神病药:系统综述与网络Meta分析
结果显示,鲁拉西酮疗效效应量最高(RR 1.72),阿立哌唑可接受性最好(RR 1.16),但部分药物可接受性较差,且缺乏维持疗效的充分研究。
要点
- 鲁拉西酮辅助治疗MDD的疗效效应量最高(RR 1.72),其次为阿立哌唑(RR 1.53)。
- 阿立哌唑可接受性最高(RR 1.16),鲁拉西酮可接受性最差(RR 2.30)。
- 临床决策需同时权衡疗效与可接受性,且维持疗效证据不足。
核心结论
- FDA批准的非典型抗精神病药辅助治疗MDD在疗效和可接受性上存在差异,应同时考虑。
- 缺乏充分且良好对照的维持疗效研究仍是知识空白。
研究设计与样本
- 系统综述与网络Meta分析,检索PubMed/MEDLINE、PsycINFO、Cochrane Library和Embase至2025年7月15日。
- 由两名独立评价者提取数据并依据Cochrane标准评估偏倚风险,采用随机效应模型合成效应量。
主要发现
- 疗效(MADRS总分较基线降低≥50%)效应量:鲁拉西酮RR 1.72(95% CrI 1.40-2.15),阿立哌唑RR 1.53(95% CrI 1.32-1.77),依匹哌唑RR 1.38(95% CrI 1.18-1.65),卡利拉嗪RR 1.20(95% CrI 1.07-1.36),喹硫平缓释片RR 1.15(95% CrI 0.96-1.35)。
- 可接受性(全因停药)效应量:阿立哌唑RR 1.16(95% CrI 0.89-1.50),卡利拉嗪RR 1.44(95% CrI 1.15-1.82),依匹哌唑RR 1.47(95% CrI 1.18-1.85),喹硫平缓释片RR 1.56(95% CrI 1.14-2.12),鲁拉西酮RR 2.30(95% CrI 1.45-3.84)。
- 次要结局(如症状缓解)和探索性结局(如有临床意义的体重增加)与共同主要结局一致。
关键数值与推荐
- 纳入标准为FDA批准用于MDD辅助治疗的非典型抗精神病药。
- 主要疗效结局为MADRS总分较基线降低≥50%,主要可接受性结局为全因停药。
临床怎么用
- 临床选择辅助抗精神病药时需综合评估疗效与可接受性,鲁拉西酮疗效最优但可接受性最差。
- 阿立哌唑可接受性最佳,可作为需长期耐受性患者的优先考虑。
局限性
- 缺乏充分且良好对照的维持疗效研究,长期证据不足。
- 纳入研究均为短期研究,结论外推至长期治疗需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Most adults living with major depressive disorder (MDD) fail to achieve remission with conventional antidepressants. The US Food and Drug Administration (FDA) has approved 5 atypical antipsychotics in MDD on the basis of their substantial evidence of efficacy and safety. OBJECTIVE: To compare the efficacy and acceptability of FDA-approved atypical antipsychotics for the adjunctive treatment of MDD in order to provide decision support to practitioners and persons with lived experience. DATA SOURCES: A systematic search was conducted using PubMed/MEDLINE, PsycINFO, the Cochrane Library, and Embase from database inception through July 15, 2025. STUDY SELECTION: Six independent raters screened publications for eligibility. Inclusion criteria were atypical antipsychotics that are FDA approved in the adjunctive treatment of MDD. DATA EXTRACTION AND SYNTHESIS: Two independent raters obtained data and examined risk of bias in accordance with the Cochrane criteria. Effect sizes were synthesized using random-effects models. Data were analyzed from August to September 2025. MAIN OUTCOMES AND MEASURES: The primary outcomes were efficacy (ie, ≥50% reduction from baseline in the total Montgomery-Åsberg Depression Rating Scale [MADRS] score) and acceptability (ie, all-cause discontinuation). RESULTS: A total of 22 short-term studies comprising 10 962 participants (aripiprazole: n = 1297; brexpiprazole: n = 1973; cariprazine: n = 1894; lumateperone: n = 483; quetiapine extended release [XR]: n = 719; and placebo: n = 4596) were included for analysis. Lumateperone had the highest effect size for efficacy (risk ratio [RR], 1.72; 95% credible interval [CrI], 1.40-2.15), followed by aripiprazole (RR, 1.53; 95% CrI, 1.32-1.77), brexpiprazole (RR, 1.38; 95% CrI, 1.18-1.65), cariprazine (RR, 1.20; 95% CrI, 1.07-1.36), and quetiapine XR (RR, 1.15; 95% CrI, 0.96-1.35). A hierarchy of acceptability was observed, with aripiprazole exhibiting the highest acceptability (RR, 1.16; 95% CrI, 0.89-1.50), followed by cariprazine (RR, 1.44; 95% CrI, 1.15-1.82), brexpiprazole (RR, 1.47; 95% CrI, 1.18-1.85), quetiapine XR (RR, 1.56; 95% CrI, 1.14-2.12), and lumateperone (RR, 2.30; 95% CrI, 1.45-3.84). Secondary outcomes (eg, symptomatic remission) and exploratory outcomes (eg, clinically significant weight gain) accorded with the coprimary outcomes. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis indicates that differences exist between adjunctive atypical antipsychotics in the treatment of MDD with respect to overall efficacy and acceptability, which should be simultaneously considered. The absence of adequate and well-controlled studies documenting maintenance efficacy of adjunctive atypical antipsychotics in MDD remains a knowledge gap.
引用
- McIntyre RS, Stahl SM, Shim SR, et al. Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry. 2026. PMID: 42090141. doi:10.1001/jamapsychiatry.2026.0658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。